Resources
Migalastat terms of reference and protocol questions
This report outlines the Migalastat 24 month review terms of reference and protocol questions.
Australian Government response to National Rural Health Commissioner’s report on improving the access, quality and distribution of allied health services in rural and remote Australia
This is the Australian Government response to the former Commissioner, Emeritus Professor Paul Worley’s report. The response outlines the work that will be undertaken to improve the capacity, quality, and distribution of allied health services to meet the needs of rural and remote Australians.
Rare Diseases – Support, Education and Training Grant Opportunity GO2815
Rare Diseases – Support, Education and Training Grant Opportunity general feedback for the information of grant applicants.
Heart Disease and Stroke – Early Detection
This document provides general feedback on the Grant Opportunity for Heart Disease and Stroke – Early Detection GO2796 for the information of grant applicants.
Heart Disease and Stroke – Support for Recovery
This document provides general feedback on the Grant Opportunity for Heart Disease and Stroke – Support for Recovery GO2797 for the information of grant applicants.
Macular disease – Population groups at risk general feedback for applicants
This document provides general feedback on the grant opportunity for Macular Disease – Consumer awareness and education – Population groups at risk for the information of grant applicants.
National Cancer Screening Register – addendum to privacy impact assessment
This report summarises developments in the national bowel and cervical screening programs and the National Cancer Screening Register since the initial privacy impact assessment was done.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 17th June 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 9th meeting on 17 June 2021.
The National Strategic Action Plan for Pain Management
The action plan aim to improve the quality of life for people living with chronic pain in Australia.
Advisory Committee for the COVID-19 Response for People with Disability – Meeting key outcomes 12 May 2021
This communique is for the meetings of the Advisory Committee on Health Emergency Response to Coronavirus (COVID-19) for People with Disability on 12 May 2021.
EAF support categories fact sheet
This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Extraordinary Assistance Fund (EAF).
Thalidomide health practitioner evidence form
This form is a template for health practitioners to provide evidence to support an eligible thalidomide survivor (patient) to receive support from the Extraordinary Assistance Fund (EAF) or the Health Care Assistance Fund (HCAF).
Making a claim to the EAF fact sheet
This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Extraordinary Assistance Fund (EAF). The EAF helps cover the costs of goods and services to assist with activities of daily living.
Making a claim to the HCAF fact sheet
This fact sheet provides information about how participants of the Australian Thalidomide Survivors Support Program can make a claim to the Health Care Assistance Fund (HCAF). The HCAF helps cover out-of-pocket health care expenses incurred as a direct result of thalidomide injuries.
HCAF support categories fact sheet
This fact sheet provides information for participants of the Australian Thalidomide Survivors Support Program about the categories of goods and services which are eligible to be claimed under the Health Care Assistance Fund (HCAF).
LSDPEP 8th meeting agenda – 19 February 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 8th meeting on 19 February 2021.
Review of CGM products – frequently asked questions for suppliers
This fact sheet answers key questions about the review of Continuous Glucose Monitoring (CGM) products provided through the National Diabetes Services Scheme (NDSS).
Review of CGM products – supplier submission form
Suppliers must use this form to make a submission to the Review of CGM products provided through the National Diabetes Services Scheme (NDSS).
Review of CGM products – submission cover sheet
Stakeholder organisations and other interested parties must use this cover sheet to make a submission to the Review of CGM products provided through the National Diabetes Services Scheme (NDSS).
LSDPEP 7th meeting agenda – 22 and 23 October 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 7th meeting on 22 and 23 October 2020.
LSDPEP 6th meeting agenda – 25 and 26 June 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 6th meeting on 25 and 26 June 2020.
LSDPEP 5th meeting agenda – 16 and 17 April 2020
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 5th meeting on 16 and 17 April 2020.
Life Saving Drugs Program – Cerliponase alfa (Brineura®) outcome statement
This document states the outcome of BioMarin's application to include cerliponase alfa on the Life Saving Drugs Program.
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
Support for Australia’s thalidomide survivors
Australian Government response to the Senate Community Affairs References Committee inquiry into support for Australia’s thalidomide survivors
Date last updated: